This positive Phase 3 data is a strong catalyst for Genmab, supporting epcoritamab's label expansion into a large DLBCL market. Traders should monitor regulatory submissions and upcoming medical meeting presentations for full data. The strong hazard ratios suggest a high likelihood of approval, which could drive upside. Watch for competitor responses from CAR-T and other bispecifics.
Price Chart
Executive Summary
Genmab announced positive topline Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, meeting the primary endpoint with statistically significant improvement in progression-free survival (PFS). The risk of disease progression and death was reduced by 60% (HR 0.40) and 56% (HR 0.44) under different censoring rules, with safety consistent with individual agents. This is a major clinical win that supports label expansion and strengthens epcoritamab's position as a core therapy in B-cell malignancies.
Key Facts
- Phase 3 EPCORE DLBCL-4 trial met primary endpoint with statistically significant improvement in PFS
- Risk reduction of 60% (HR 0.40, 95% CI 0.30-0.55, p<0.0001) in the U.S. and 56% (HR 0.44, 95% CI 0.33-0.60, p<0.0001) outside the U.S.
- Safety profile of epcoritamab plus lenalidomide consistent with known profiles of individual agents
- Genmab and AbbVie will engage global regulatory authorities for potential label expansion
- Epcoritamab is already approved in >65 territories for certain lymphoma indications
Financial Impact
Potential label expansion in RR DLBCL could significantly increase epcoritamab revenue; no specific financial guidance provided in the filing.
Risk Factors
- Regulatory approval is not guaranteed; full data and safety details are pending
- Competition from CAR-T therapies and other bispecific antibodies in DLBCL
- Potential for unforeseen safety signals in larger patient populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000100 |
| Document: gmab_20260629x6k.htm | 0001434265-26-000100 |
| Document: 0001434265-26-000100-index-headers.html | 0001434265-26-000100 |
| Document: 0001434265-26-000100-index.html | 0001434265-26-000100 |
| Document: 0001434265-26-000100.txt | 0001434265-26-000100 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $33.53 $32.65 | ▼ −2.62% | ▼ −1.96% | $34.51 (+2.94%) |
Aug 12, 2026 7w ago | 6-K | $31.42 $34.11 | ▲ +8.56% | ▲ +9.01% | $34.51 (+9.85%) |
Aug 11, 2026 7w ago | 6-K | $30.85 $32.96 | ▲ +6.84% | ▲ +7.24% | $34.51 (+11.88%) |
Aug 6, 2026 8w ago | 6-K | $29.83 $31.34 | ▲ +5.06% | ▲ +3.85% | $34.51 (+15.71%) |
Jul 15, 2026 11w ago | 6-K | $29.08 $28.85 | ▼ −0.79% | ▲ +0.19% | $34.51 (+18.69%) |
Jun 29, 2026 13w ago | 6-K | $27.47 $28.01 | ▲ +1.97% | ▲ +1.36% | $34.51 (+25.65%) |
Jun 17, 2026 15w ago | 6-K | $25.39 $25.87 | ▲ +1.87% | ▲ +2.91% | $34.51 (+35.94%) |
Jun 16, 2026 15w ago | 6-K | $24.74 $25.94 | ▲ +4.85% | ▲ +7.08% | $34.51 (+39.51%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.51 (+40.42%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.51 (+40.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access